Deals
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says
This article is for subscribers only.
Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed takeover of Germany’s Evotec SE in cash, according to Chief Executive Officer Helen Torley.
“We feel confident in being able to fund this as a fully cash deal,” Torley said in an interview. “Equity will not be used. As we take on some debt, our strong cash flow will be able to bring us down to two times leverage very rapidly” after the deal closes, she said.